About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Portland | 8,670 Studies Near You | Clareo Health

Clinical Trials LocationsPortland

Clinical Trials in Portland

Discover 8,670 clinical trials near Portland, Oregon. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 1361-1380 of 8,670 trials

RECRUITINGPhase 2< 1 mile

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

NCT03801434

This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

BCR-JAK2 Fusion Protein ExpressionBlasts 20 Percent or Less of Peripheral Blood White CellsBlasts More Than 5 Percent of Bone Marrow Nucleated Cells+9 more

William Shomali10 participantsStarted Nov 2019

Palo Alto, California, United States • Portland, Oregon, United States • Salt Lake City, Utah, United States +1 more locations

COMPLETEDNA< 1 mile

SMART TRENDS Study

NCT05957406

A multicenter, interventional, feasibility comparison with historical controls

Moderate to High-risk Noncardiac Surgery

Edwards Lifesciences296 participantsStarted Jul 2023

Sacramento, California, United States • Ann Arbor, Michigan, United States • Detroit, Michigan, United States +5 more locations

Find Trials by Condition in Portland

Breast Cancerin Portland Lung Cancerin Portland Prostate Cancerin Portland Colorectal Cancerin Portland Melanomain Portland Leukemiain Portland Lymphomain Portland Pancreatic Cancerin Portland Ovarian Cancerin Portland Brain Cancerin Portland Diabetes

Data from ClinicalTrials.govTerms

RECRUITINGPhase 3< 1 mile

Early Amiodarone in Shockable Cardiac Arrest

NCT06680869

The primary objective of this pilot, pragmatic stepped-wedge cluster randomized trial is to evaluate if a modified cardiac arrest treatment algorithm calling for the administration of the initial amiodarone dose one 2-minute cycle earlier than current guidelines (during the same cycle as the initial dose of epinephrine) improves the time to amiodarone delivery in those with out-of-hospital cardiac arrest due to refractory ventricular fibrillation or ventricular tachycardia compared to usual care.

Oregon Health and Science University585 participantsStarted Jan 2025

Portland, Oregon, United States

Active Not RecruitingPhase 2< 1 mile

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant. The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.

Uterine NeoplasmsUterine Cervical NeoplasmsBiliary Tract Neoplasms+3 more

Seagen, a wholly owned subsidiary of Pfizer217 participantsStarted Jan 2021

Phoenix, Arizona, United States • Tempe, Arizona, United States • Tucson, Arizona, United States +103 more locations

Active Not RecruitingPhase 3106 miles

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.

Follicular LymphomaMarginal Zone Lymphoma

Incyte Corporation654 participantsStarted Apr 2021

Concord, California, United States • Greenbrae, California, United States • Pasadena, California, United States +258 more locations

Active Not RecruitingPhase 2115 miles

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

NCT05241860

This phase II trial examines antiandrogen therapy interruptions in patients with hormone-sensitive prostate cancer that has spread to other places in the body (metastatic) responding exceptionally well to androgen receptor-pathway inhibitor therapy. The usual treatment for patients with metastatic prostate cancer is to receive hormonal medications including a medication to decrease testosterone levels in the body and a potent oral hormonal medication to block growth signals from male hormones (like testosterone) in the cancer cells. Patients whose cancer is responding exceptionally well to this therapy may take a break from these medications according to their doctor's guidance. This trial may help doctors determine if stopping treatment can allow for testosterone recovery.

Castration-Sensitive Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v8+2 more

Alliance for Clinical Trials in Oncology79 participantsStarted Nov 2022

Phoenix, Arizona, United States • Fort Smith, Arkansas, United States • Little Rock, Arkansas, United States +323 more locations

COMPLETEDPhase 3121 miles

A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age

NCT04464707

The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of CM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of CM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical outcomes in participants exposed to Fremanezumab The total duration of the study is planned to be 75 months.

Teva Branded Pharmaceutical Products R&D, Inc.292 participantsStarted Sep 2020

Little Rock, Arkansas, United States • Banning, California, United States • Loma Linda, California, United States +86 more locations

COMPLETEDPhase 3145 miles

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

NCT04578834

The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

IgA Nephropathy

Novartis Pharmaceuticals518 participantsStarted Jan 2021

Glendale, Arizona, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +174 more locations

COMPLETEDPhase 2145 miles

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

NCT04699630

This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).

Metastatic Breast CancerLocally Advanced Breast Cancer

SCRI Development Innovations, LLC121 participantsStarted May 2021

Birmingham, Alabama, United States • Springdale, Arkansas, United States • Duarte, California, United States +8 more locations

RECRUITINGNA145 miles

ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

NCT05172973

The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve.

Aortic Valve InsufficiencyAortic Valve Stenosis

Edwards Lifesciences200 participantsStarted Nov 2023

Newport Beach, California, United States • San Francisco, California, United States • San Francisco, California, United States +32 more locations

Enrolling By InvitationPhase 2145 miles

Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury

NCT05826912

The purpose of this study is to determine if experimental drug treatment improves recovery after TBI as compared to a control (placebo) group. Changes in recovery will be measured throughout the study. The study drugs listed below are approved by the U.S. Food and Drug Administration (FDA) but are being used "off-label" in this study. This means that the drugs are not currently approved to treat TBI.

Traumatic Brain Injury

University of California, San Francisco672 participantsStarted Aug 2024

San Francisco, California, United States • Indianapolis, Indiana, United States • Lexington, Kentucky, United States +15 more locations

Active Not RecruitingNA145 miles

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)

NCT05820087

The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors.

Renal CancerTumor, SolidKidney Cancer+2 more

HistoSonics, Inc.67 participantsStarted Jan 2024

Los Angeles, California, United States • Los Angeles, California, United States • Mission Viejo, California, United States +12 more locations

Active Not RecruitingPhase 3204 miles

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

Triple Negative Breast Neoplasms

AstraZeneca923 participantsStarted Jun 2019

Whittier, California, United States • Whittier, California, United States • Fort Myers, Florida, United States +257 more locations

COMPLETEDPhase 3259 miles

Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)

NCT04684524

Primary Objective: * To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population with allergic fungal rhinosinusitis (AFRS) Secondary Objectives: * To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population with allergic fungal rhinosinusitis (AFRS) at Week 24 * To assess the efficacy of dupilumab to reduce the need for rescue treatments * To evaluate the efficacy of treatment with dupilumab in improving symptoms in AFRS * To evaluate the efficacy of dupilumab to reduce nasal polyp formation in participants with AFRS * To evaluate the efficacy of dupilumab in improving overall symptom severity and quality of life in AFRS * To evaluate the efficacy of dupilumab in improving sense of smell in participants with AFRS * To explore the effect of dupilumab as assessed by three-Dimensional CT volumetric measurement of the paranasal sinuses * To evaluate the safety and tolerability of dupilumab when administered to participants with AFRS * To evaluate the pharmacokinetics (PK) of dupilumab in participants with AFRS * To characterize the effect of dupilumab on total IgE and specific IgE * To assess immunogenicity to dupilumab in participants with AFRS

Allergic Fungal Rhinosinusitis

Sanofi62 participantsStarted Dec 2020

Tampa, Florida, United States • Atlanta, Georgia, United States • Louisville, Kentucky, United States +44 more locations

Active Not RecruitingPhase 1259 miles

[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

NCT06229366

ACCEL is a multicenter, open label phase Ia/Ib/II study of \[Ac-225\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.

Prostate CancerMetastatic Castration-resistant Prostate CancerOligometastatic Prostate Carcinoma+1 more

Eli Lilly and Company142 participantsStarted Apr 2024

Hamilton, Canada • Montreal, Canada • Montreal, Canada +4 more locations

COMPLETEDPhase 1/2483 miles

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

NCT05453578

This is a phase 1b/2 study of a single dose of intravenous (IV) bacteriophage in males and non-pregnant females, at least 18 years old, diagnosed with Cystic Fibrosis (CF). This clinical trial is designed to assess the safety and microbiological activity of bacteriophage product Walter Reed Army Institute of Research- PAM-Cystic Fibrosis1 (WRAIR-PAM-CF1), directed at Pseudomonas aeruginosa in clinically stable CF individuals chronically colonized with P. aeruginosa. WRAIR-PAM-CF1 is a 4 component anti-pseudomonal bacteriophage mixture containing between 4 x 10\^7 and 4 x 10\^9 Plaque Forming Units (PFU) of bacteriophage. Enrollment will occur at up to 20 clinical sites in the United States. In stage 1, two eligible subjects will be assigned to each of the three dosing arms receiving a single dosage of the IV bacteriophage therapy (4 x 10\^7 PFU, 4 x 10\^8 PFU, and 4 x 10\^9 PFU; total of 6 sentinel subjects), followed by 30 plus or minus 7 days observation period. If no Serious Adverse Events (SAEs)(related to the study product) are identified during the 96 hours after bacteriophage administration for all Sentinel Subjects in Stage 1, the study will proceed to Stage 2. In Stage 2a, 32 subjects will be enrolled into one of 4 arms (placebo IV, 4 x 10\^7 PFU, 4 x 10\^8 PFU, and 4 x 10\^9 PFU) in a 1:1:1:1 allocation. An interim analysis will be performed after all subjects have completed follow up visit 5 on Day 8+3 to select the IV bacteriophage dose with the most favorable safety and microbiological activity profile. During Stage 2b, subjects will be randomized into the bacteriophage (dose selected based on Interim Analysis following Stage 2a) or placebo arm. The final sample size is expected to be up to 72 subjects total with up to 25 subjects in the placebo arm and up to 25 subjects in the Stage 2b bacteriophage dose.

Bacterial Disease CarrierCystic Fibrosis

National Institute of Allergy and Infectious Diseases (NIAID)72 participantsStarted Oct 2022

Tucson, Arizona, United States • La Jolla, California, United States • La Jolla, California, United States +16 more locations

RECRUITINGPhase 2535 miles

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

NCT06228053

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

Metastatic Castration-resistant Prostate Cancer

Syntrix Biosystems, Inc.53 participantsStarted Nov 2024

Los Angeles, California, United States • San Francisco, California, United States • Ann Arbor, Michigan, United States +3 more locations

COMPLETEDPhase 3559 miles

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT04125836

The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial. Patients completing the main part of the trial will be offered 52 weeks continued open-label treatment in an extension part.

Camurus AB135 participantsStarted Oct 2019

Los Angeles, California, United States • Palo Alto, California, United States • Miami, Florida, United States +65 more locations

COMPLETEDPhase 3559 miles

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

NCT04175613

This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue to receive open-label apremilast therapy. The study will consist of up to 208 weeks of long-term treatment followed by an 8-week observational follow-up phase.

Amgen160 participantsStarted Dec 2019

Phoenix, Arizona, United States • Fort Smith, Arkansas, United States • Irvine, California, United States +47 more locations

Active Not RecruitingPhase 3559 miles

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06253221

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

Cardiomyopathy, Hypertrophic

Bristol-Myers Squibb44 participantsStarted Apr 2024

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +44 more locations

PreviousPage 69 of 434Next

in Portland

Heart Diseasein Portland